MyFinsight
Home
Blog
About
Back
Income Statement
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)
source: myfinsight.com
Net loss
attributable to common...
-$47,835,431
Interest income
$46,176
(3290.31%↑ Y/Y)
Deemed dividend
$46,113,903
Net loss
-$1,721,528
(66.04%↑ Y/Y)
Total other income,
net
$43,148
Interest expense
$3,028
(125.63%↑ Y/Y)
Total operating costs
$1,764,676
(-65.19%↓ Y/Y)
General and
administrative expenses
$1,320,002
(-73.74%↓ Y/Y)
Research and development
expenses
$444,674
(938.01%↑ Y/Y)
Back